Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2020

Open Access 01-08-2020 | Ovarian Cancer | Review Article

Organoid of ovarian cancer: genomic analysis and drug screening

Authors: H.-D. Liu, B.-R. Xia, M.-Z. Jin, G. Lou

Published in: Clinical and Translational Oncology | Issue 8/2020

Login to get access

Abstract

Ovarian cancer is the most common malignant tumors of the female reproductive system, and its standard treatments are cytoreductive surgery and platinum-based adjuvant chemotherapy. Great advances have been achieved in novel treatment strategies, including targeted therapy and immunotherapy. However, ovarian cancer has the highest mortality rate among gynecological tumors due to therapeutic resistance and the gap between preclinical data and actual clinical efficacy. Organoids are a 3D culture model that markedly affects gene analysis, drug screening, and drug sensitivity determination of tumors, especially when used in targeted therapy and immunotherapy. In addition, organoid can lead to advances in the preclinical research of ovarian cancer due to its convenient cultivation, good genetic stability, and high homology with primary tumors.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.PubMed
2.
Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomark Prev. 2017;26(4):444–57.
3.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.PubMed
4.
Es HA, Montazeri L, Aref AR, et al. Personalized cancer medicine: an organoid approach. Trends Biotechnol. 2018;36(4):358–71.
5.
Jin MZ, Han RR, Qiu GZ, et al. Organoids: an intermediate modeling platform in precision oncology. Cancer Lett. 2018;414:174–80.PubMed
6.
Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:21–6.
7.
Maru Y, Hippo Y. Current status of patient-derived ovarian cancer models. Cells. 2019;8(5):505.PubMedCentral
8.
Sawyers C. Targeted cancer therapy. Nature. 2004;4329(7015):294–7.
9.
Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. CancerRes. 2003;63(24):8634–47.
10.
Chijiwa T, Kavai K, Noguchi A, et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol. 2015;47(1):61–70.PubMedPubMedCentral
11.
Jung J, Seol HS, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat. 2018;50(1):1–10.PubMed
12.
Ga H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318–25.
13.
Kawaguchi T, Foster BA, Young J, et al. Current update of patient-derived xenograft model for translational breast cancer research. J Mammary Gland Biol Neoplasia. 2017;22(2):131–9.PubMedPubMedCentral
14.
Wu J, Liu X, Nayak SG, et al. Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele. PLoS ONE ONE. 2017;12(9):e0184984.
15.
Lee WS, Kim HY, Seok JY, et al. Genomic profiling of patient-derived colon cancer xenograft models. Medicine(Baltimore). 2014;93(28):e298.
16.
Erriquez J, Olivero M, Mittica G, et al. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget. 2016;24(3):26181–91.
17.
George E, Kim H, Krepler C, et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight. 2017;2(1):e89760.PubMedPubMedCentral
18.
Colombo PE, du Manoir S, Orsett B, et al. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Pierre-Emmanuel Colombo. Oncotarget. 2015;6(29):28327–40.PubMedPubMedCentral
19.
Ricci F, Guffanti F, Damia G, et al. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. Mol Cancer. 2017;16(1):97.PubMedPubMedCentral
20.
Guffanti F, Fratelli M, Ganzinelli M, et al. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. Oncotarget. 2018;9(37):24707–17.PubMedPubMedCentral
21.
Caponigro G, Sellers WR. Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov. 2011;10(3):179–87.PubMed
22.
Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumor grafts in patients with advanced cancer. Mol Cancer Ther. 2011;10(8):1311–6.PubMedPubMedCentral
23.
Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338–50.PubMedPubMedCentral
24.
Kryczek I, Liu S, Roh M, et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer. 2012;130(1):29–39.PubMed
25.
Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267–84.PubMed
26.
Stewart JM, Shaw PA, Gedye C, et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA. 2011;108(16):6468–73.PubMedPubMedCentral
27.
28.
Klymenko Y, Kim O, Loughran E, et al. Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis. Oncogene. 2017;36(42):5840–51.PubMedPubMedCentral
29.
Mo L, Pospichalova V, Huang Z, et al. Ascites increases expression/function of multidrug resistance proteins in ovarian cancer cells. PLoS ONE ONE. 2015;10(7):e0131579.
30.
Bapat SA, Mali AM, Koppikar CB, et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65(8):3025–9.PubMed
31.
Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.PubMed
32.
Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506–11.PubMed
33.
Zhang Y, Xu W, Guo H, et al. NOTCH1 signaling regulates self-renewal and platinum chemoresistance of cancer stem–like cells in human non-small cell lung cancer. Cancer Res. 2017;77(11):3082–91.PubMed
34.
Ishiguro T, Sato A, Ohata H, et al. Establishment and characterization of an in vitro model of ovarian cancer stem-like cells with an enhanced proliferative capacity. Cancer Res. 2016;76(1):150–60.PubMed
35.
Raghavan S, Mehta P, Ward MR, et al. Personalized medicine-based approach to model patterns of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids. Clin Cancer Res. 2017;23(22):6934–45.PubMedPubMedCentral
36.
Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176–87.PubMedPubMedCentral
37.
Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, Adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141(5):1762–72.PubMed
38.
Boj SF, Hwang CL, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1–2):324–38.PubMed
39.
40.
Nakamura H, Sugano M, Ishii G, et al. Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells. Lung Cancer. 2019;134:100–7.PubMed
41.
42.
Sugarman R, Patel R, Saif MW, et al. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opin Drug Metab Toxicol. 2019;15(7):541–52.PubMed
43.
Gendoo DMA, Denroche RE, Haibe-Kains B, et al. Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. PLoS Comput Biol. 2019;15(1):e1006596.PubMedPubMedCentral
44.
Ponz-Sarvise M, Corbo V, Tuveson DA, et al. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer. Clin Cancer Res. 2019;25(22):6742–55.PubMedPubMedCentral
45.
Yan Z, Ohuchida K, Nakamura M, et al. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. J Exp Clin Cancer Res. 2019;38(1):221.PubMedPubMedCentral
46.
Choi SI, Jeon AR, Kim YH, et al. Development of patient-derived preclinical platform for metastatic pancreatic cancer: pdox and a subsequent organoid model system using percutaneous biopsy samples. Front Oncol. 2019;9:875.PubMedPubMedCentral
47.
48.
Hennig A, Wolf L, Welsch T, et al. CFTR expression analysis for subtyping of human pancreatic cancer organoids. Stem Cells Int. 2019;2019:1024614.PubMedPubMedCentral
49.
Münch NS, Fang HY, Quante M, et al. High-fat diet accelerates carcinogenesis in a mouse model of barrett’s esophagus via interleukin 8 and alterations to the gut microbiome. Gastroenterology. 2019;157(2):492–506.e2.PubMed
50.
Li J, Xu H, Zhan X, et al. Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening. J Cancer Res Clin Oncol. 2019;145(11):2637–47.PubMed
51.
Wang X, Liang Q, Yu J, et al. C8orf76 promotes gastric tumorigenicity and metastasis by directly inducing lncrna dusp5p1 and associates with patient outcomes. Clin Cancer Res. 2019;25(10):3128–40.PubMed
52.
Holokai L, Chakrabarti J, Zavros Y, et al. Increased programmed death-ligand 1 is an early epithelial cell response to helicobacter pylori infection. PLoS Pathog. 2019;15(1):e1007468.PubMedPubMedCentral
53.
Chatterjee S, Bhat V, Raouf A, et al. Paracrine crosstalk between fibroblasts and ER+ breast cancer cells creates an IL1β-enriched niche that promotes tumor growth. iScience. 2019;19:388–401.PubMedPubMedCentral
54.
Mazzucchelli S, Piccotti F, Corsi F, et al. Establishment and morphological characterization of patient-derived organoids from breast cancer. Biol Proced Online. 2019;21:12.PubMedPubMedCentral
55.
Sharick JT, Jeffery JJ, Skala MC, et al. Cellular metabolic heterogeneity in vivo is recapitulated in tumor organoids. Neoplasia. 2019;21(6):615–26.PubMedPubMedCentral
56.
Mollica PA, Booth-Creech EN, Bruno RD, et al. 3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels. Acta Biomater. 2019;95:201–13.PubMedPubMedCentral
57.
58.
Driehuis E, Spelier S, Oliveira S, et al. Patient-derived head and neck cancer organoids recapitulate egfr expression levels of respective tissues and are responsive to egfr-targeted photodynamic therapy. J Clin Med. 2019;8(11).
59.
Driehuis E, Kolders S, Clevers H, et al. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov. 2019;9(7):852–71.PubMed
60.
Linkous A, Balamatsias D, Fine HA, et al. Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep. 2019;26(12):3203–3211.e5.PubMedPubMedCentral
61.
Nath D, Li X, Kotula L, et al. Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Commun Signal. 2019;17(1):120.PubMedPubMedCentral
62.
Adams EJ, Karthaus WR, Sawyers CL, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408–12.PubMedPubMedCentral
63.
Wadosky KM, Wang Y, Goodrich DW, et al. Generation of tumor organoids from genetically engineered mouse models of prostate cancer. J Vis Exp. 2019;13(148).
64.
Elbadawy M, Usui T, Sasaki K, et al. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. Cancer Sci. 2019;110(9):2806–21.PubMedPubMedCentral
65.
Mullenders J, de Jongh E, Clevers HC, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S A. 2019;116(10):4567–74.PubMedPubMedCentral
66.
Wang S, Kim J, Jung Y, et al. Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse. Biomaterials. 2019;219:119375.PubMed
67.
Sun L, Wang Y, Hui L, et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol. 2019;21(8):1015–26.PubMed
68.
Artegiani B, van Voorthuijsen L, Clevers H, et al. Probing the tumor suppressor function of bap1 in crispr-engineered human liver organoids. Cell Stem Cell. 2019;24(6):927–943.e6.PubMed
69.
Li L, Knutsdottir H, Selaru FM, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight. 2019;4(2).
70.
Saborowski A, Wolff K, Saborowski M, et al. Murine liver organoids as a genetically flexible system to study liver cancer in vivo and in vitro. Hepatol Commun. 2019;3(3):423–36.PubMedPubMedCentral
71.
72.
Costales-Carrera A, Fernández-Barral A, Muñoz A, et al. Plocabulin displays strong cytotoxic activity in a personalized colon cancer patient-derived 3d organoid assay. Mar Drugs. 2019;17(11).
73.
Rudloff I, Jardé T, Nold MF, et al. Molecular signature of interleukin-22 in colon carcinoma cells and organoid models. Transl Res. 2019;216:1–22.PubMed
74.
Fernández-Barral A, Costales-Carrera A, Barbáchano A, et al. Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids. FEBS J. 2019;287(1):53–72.PubMedPubMedCentral
75.
Ng S, Tan WJ, Kurisawa M, et al. Mechanically and chemically defined hydrogel matrices for patient-derived colorectal tumor organoid culture. Biomaterials. 2019;219:119400.PubMed
76.
Bolhaqueiro ACF, Ponsioen B, Kops GJPL, et al. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids. Nat Genet. 2019;51(5):824–34.PubMed
77.
Szvicsek Z, Oszvald Á, Wiener Z, et al. Extracellular vesicle release from intestinal organoids is modulated by Apc mutation and other colorectal cancer progression factors. Cell Mol Life Sci. 2019;76(12):2463–76.PubMedPubMedCentral
78.
Sakahara M, Okamoto T, Yao R, et al. IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Cancer Sci. 2019;110(4):1293–305.PubMedPubMedCentral
79.
Takeda H, Kataoka S, Oshima M, et al. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc Natl Acad Sci U S A. 2019;116(31):15635–44.PubMedPubMedCentral
80.
Matsui S, Okabayashi K, Kitagawa Y, et al. Interleukin-13 and its signaling pathway is associated with obesity-related colorectal tumorigenesis. Cancer Sci. 2019;110(7):2156–65.PubMedPubMedCentral
81.
82.
83.
Blanchard TG, Czinn SJ, Banerjee A, et al. Identification of cross talk between foxm1 and rassf1a as a therapeutic target of colon cancer. Cancers (Basel). 2019;11(2).
84.
85.
Maru Y, Tanaka N, Hippo Y, et al. Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma. Cancer Sci. 2019;110(9):2992–3005.PubMedPubMedCentral
86.
87.
Boretto M, Maenhoudt N, Vankelecom H, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019;21(8):1041–51.PubMed
88.
Kopper O, de Witte CJ, Clevers H, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838–49.PubMed
89.
Grassi L, Alfonsi R, Bonci D, et al. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis. 2019;10(3):201.PubMedPubMedCentral
90.
Kopper O, De Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 2019;25(5):838–49.PubMed
91.
Onuma K, Ochiai M, Orihashi K, et al. Genetic reconstitution of tumorigenesis in primary intestinal cells. Proc Natl Acad Sci USA. 2013;110(27):11127–332.PubMedPubMedCentral
92.
Maru Y, Onuma K, Ochiai M, et al. Hippo, shortcuts to intestinal carcinogenesis by genetic engineering in organoids. Cancer Sci. 2019;110(3):858–66.PubMedPubMedCentral
93.
Maru Y, Tanaka N, Itami M, et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol. 2019;154(1):189–98.PubMed
94.
van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–45.PubMedPubMedCentral
95.
Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373–86 ).PubMed
96.
Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424–35.PubMedPubMedCentral
97.
Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell. 2016;18(6):827–38.PubMed
98.
Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373–386.e10.PubMed
99.
Lee HG, Shin SJ, Chung HW, et al. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell. J Gynecol Oncol. 2017;28(2):e14.PubMed
100.
Hirst J, Pathak HB, Hyter S, et al. Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties. Cancer Res. 2018;78(15):4370–85.PubMedPubMedCentral
101.
Katsuda T, Kawamata M, Hagiwara K, et al. Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity. Cell Stem Cell. 2017;20(1):41–55.PubMed
102.
Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2010;6(6):733–46.PubMed
103.
Ogihara T, Arakawa H, Jomura T, et al. Utility of human hepatocyte spheroids without feeder cells for evaluation of hepatotoxicity. J Toxicol Sci. 2017;42(4):499–507.PubMed
104.
Yu KN, Nadanaciva S, Rana P, et al. Prediction of metabolism-induced hepatotoxicity on three-dimensional hepatic cell culture and enzyme microarrays. Arch Toxicol. 2018;92(3):1295–310.PubMed
105.
Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404–21.PubMedPubMedCentral
106.
Soragni A, Janzen DM, Johnson LM, et al. A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell. 2016;29(1):90–103.PubMed
107.
Hardwick N, Frankel PH, Cristea M. New approaches for immune directed treatment for ovarian cancer. Curr Treat Options Oncol. 2016;17(3):14.PubMed
108.
Nayama M, Collinet P, Salzet M, et al. Immunological aspects of ovarian cancer: therapeutic perspectives. J Gynecol Obstet Biol Reprod (Paris). 2016;45(9):1020–36.
109.
110.
Agliari E, Biselli E, De Ninno A, et al. Cancer-driven dynamics of immune cells in a microfluidic environment. Sci Rep. 2014;4:6639.PubMedPubMedCentral
111.
Hsu T-H, Kao Y-L, Lin W-L, et al. The migration speed of cancer cells influenced by macrophages and myofibroblasts co-cultured in a microfluidic chip. Integr Biol (Camb). 2012;4(2):177–82.
112.
Mattei F, Schiavoni G, De Ninno A, et al. A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. J Immunotoxicol. 2014;11(4):337–46.PubMed
113.
Nozaki K, Mochizuki W, Matsumoto Y, et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J Gastroenterol. 2016;51(3):206–13.PubMedPubMedCentral
114.
Zumwalde NA, Haag JD, Sharma D, et al. Analysis of immune cells from human mammary ductal epithelial organoids reveals Vδ2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate. Cancer Prev Res (Phila). 2016;9(4):305–16.
115.
Chakrabarti J, Holokai L, Syu L, et al. Mouse-derived gastric organoid and immune cell co-culture for the study of the tumor microenvironment. Methods Mol Biol. 2018;1817:157–68.PubMed
116.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed
117.
Hubert CG, Rivera M, Spangler LC, et al. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 2016;76(8):2465–77.PubMedPubMedCentral
118.
Schnalzger TE, de Groot MH, Zhang C, et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO J. 2019;38(12):e100928.PubMedPubMedCentral
119.
Ando Y, Siegler EL, Ta HP, et al. Evaluating CAR-T Cell therapy in a hypoxic 3D tumor model. Adv Healthc Mater. 2019;8(5):e1900001.PubMedPubMedCentral
120.
Salama NR, Hartung ML, Muller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11(6):385–99.PubMedPubMedCentral
121.
Scanu T, Spaapen RM, Bakker JM, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe. 2015;17(6):763–74.PubMed
122.
Workman MJ, Mahe MM, Trisno S, et al. Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med. 2017;23(1):49–59.PubMed
123.
Ohlund D, -Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.PubMedPubMedCentral
124.
Zhang AW, McPherson A, Milne K, et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell. 2018;173(7):1755.e22–69.e22.
Metadata
Title
Organoid of ovarian cancer: genomic analysis and drug screening
Authors
H.-D. Liu
B.-R. Xia
M.-Z. Jin
G. Lou
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02276-8

Other articles of this Issue 8/2020

Clinical and Translational Oncology 8/2020 Go to the issue

Research Article

Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis

Research Article

Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer

Research Article

Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population

Research Article

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Research Article

IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma

Research Article

Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits